Page Menu

Tumor Biology Department Metrics

View the clinical trials, grants and publications from the Tumor Biology Department.

Clinical Trials
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable ()

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib (); Not Applicable (); Placebo (); Xalkori (Crizotinib)

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); Bevacizumab (); Pembrolizumab (Keytruda)

InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Condition: Genitourinary
Intervention: Ifosfamide (); Not Applicable (); Taxol (paclitaxel); cisplatin (); paclitaxel ()

A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
Condition: Breast
Intervention: DC1 Vaccine (); Herceptin (Trastuzumab); Paraplatin (carboplatin); Pertuzumab (); Taxotere (docetaxel); Trastuzumab (); carboplatin (); docetaxel (); rhuMAb HER2 (Trastuzumab)

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Plinabulin (); Yervoy (Ipilimumab)

Sequential Maintenance with Thoracic Radiotherapy and Durvalumab (MEDI4736) monotherapy or Durvalumab (MEDI 4736) combinations (Tremelimumab or Olaparib) in patients with Extensive Stage-Small Cell Lung Cancer after first line Platinum-based Chemotherapy
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); CP-675,206 (tremelimumab); Durvalumab (); MEDI4736 (Durvalumab); Olaparib (Lynparza); tremelimumab ()

Linking the Skin and Gut Microbiome to Immunosuppression in Skin Cancer
Condition: Cutaneous

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer(Lung-MAP Screening Study)
Condition: Thoracic
Intervention: AG-014447 (Rucaparib); ALT-803 (); AMG 510 (Sotorasib); Alimta (Pemetrexed); Avelumab (); BMN-673 (Talazoparib); CO-338 (Rucaparib); Dexamethasone (); Folic Acid (); Gemzar (gemcitabine); IMC-1121B (Ramucirumab); MSB00100718C (Avelumab); PF-01367338-BW (Rucaparib); Pembrolizumab (Keytruda); Pemetrexed (); Ramucirumab (); Rucaparib (); Selpercatinib (); Talazoparib (); Taxotere (docetaxel); Vitamin B12 (); docetaxel (); gemcitabine ()

A Phase 1/2 Study of REGN5093 in Patients with Met-Altered Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: REGN5093 ()

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer
Condition: Immunotherapy
Intervention: AMG 757 (); Pembrolizumab (Keytruda); Tarlatamab (AMG 757)

Randomized Trial of Prolonged Use of Negative Pressure Wound Therapy in Patients Undergoing Surgical Procedures for the Management of Gastrointestinal Malignancies
Condition: Gastrointestinal Tumor

A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors
Condition: Multiple
Intervention: ONCR-177 (); Pembrolizumab (Keytruda)

Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); gemcitabine (); paclitaxel ()

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Condition: Multiple
Intervention: Faslodex (fulvestrant); Herceptin (Trastuzumab); Trastuzumab (); Tucatinib (); fulvestrant (); rhuMAb HER2 (Trastuzumab)

A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy Of PF-07284890 (ARRY-461) In Participants With BRAF V600-Mutant Solid Tumors With And Without Brain Involvement
Condition: Multiple
Intervention: Binimetinib (); Midazolam (); PF-07284890 ()

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Condition: Thoracic
Intervention: Not Applicable (); Pembrolizumab (Keytruda)

A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)
Condition: Multiple
Intervention: ICT01 (); Not Applicable (); Pembrolizumab (Keytruda)

A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study To Investigate The Safety, Pharmacokinetics And Preliminary Efficacy Of Intravenous NBF-006 In Patients With Non-Small Cell Lung, Pancreatic, Or Colorectal Cancer Followed By A Dose Expansion Study In Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: NBF-006 ()

Thoracic Program Trial Selection Protocol
Condition: Thoracic

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Pembrolizumab versus Docetaxel with or without Ramucirumab in Patients with Previously Treated Non-Small Cell Lung Cancer (Acclaim 2)
Condition: Thoracic
Intervention: GPX-001 (); IMC-1121B (Ramucirumab); Pembrolizumab (Keytruda); Ramucirumab (); Taxotere (docetaxel); docetaxel ()

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Alimta (Pemetrexed); Durvalumab (); MEDI4736 (Durvalumab); Paraplatin (carboplatin); Pemetrexed (); Radiotherapy (); Taxol (paclitaxel); carboplatin (); cisplatin (); etoposide (); paclitaxel ()

A Dose-escalation Study of the Safety and Pharmacology of DAN 222 in Subjects with Metastatic Breast Cancer
Condition: Breast
Intervention: DAN-222 (); Niraparib ()

  • Administrative Supplements to Cancer Center Support Grants to Strengthen the Research, Training, and Outreach Capacity of the Geographic Management of Cancer Health Disparities Program
    Sponsor: Nat Institutes of Health
    PI:Cleveland, J.,Project PI:Gwede, C.,Project PI:Meade, C.
  • Administrative Supplements to Cancer Center Support Grants to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network
    Sponsor: Nat Institutes of Health
    PI:Cleveland, J.,Project PI:Gwede, C.,Project PI:Meade, C.
  • Moffitt Cancer Center Support Grant Years 24-27
    Sponsor: Nat Institutes of Health
    PI:Cleveland, J.,Project PI:Kanetsky, P.,Project PI:Kissil, J.,Project PI:Brandon, T.,Project PI:Conejo-Garcia, J.,Project PI:Duckett, D.,Project PI:Gray, J.,Project PI:Jim, H.,Project PI:Locke, F.,Core PI/Director:Springer, B.,Core PI/Director:Vadaparampil, S.,Core PI/Director:Wright, K.
  • Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement
    Sponsor: Nat Institutes of Health
    PI (Contact):Cleveland, J.,PI:Eroglu, Z.
  • 2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
    Sponsor: Nat Institutes of Health
    PI (Contact):Munoz-Antonia, T.,PI:Sullivan, D.
  • Local and Systemic Control of Multiple Myeloma Colonization and Growth by MMP-13
    Sponsor: Nat Institutes of Health
    PI:Lynch, C.
  • Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation
    Sponsor: Nat Institutes of Health
    PI:Lau, E.
  • New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
    Sponsor: Nat Institutes of Health
    PI:Cleveland, J.
  • Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach
    Sponsor: Nat Institutes of Health
    PI (Contact):Lynch, C.,PI (MPI):Basanta Gutierrez, D.
  • State of FL-License Plate Funds
    Sponsor: State of Florida
    PI:Cleveland, J.
  • Targeted degradation of RNAs by using small molecules
    Sponsor: Nat Institutes of Health
    PI:Cleveland, J.
  • CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
    Sponsor: Nat Institutes of Health
    PI:Chellappan, S.
  • Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis
    Sponsor: Nat Institutes of Health
    PI:Smalley, K.
  • Targeting the suppressive immune microenvironment in leptomeningeal melanoma metastases
    Sponsor: Nat Institutes of Health
    PI:Smalley, K.
  • Functional characterization of prostate cancer risk loci by high throughput sequencing
    Sponsor: Nat Institutes of Health
    PI:Wang, L.
  • St of FL Appropriation-CET Developmental Funds-12
    Sponsor: State of Florida
    PI (Contact):Cleveland, J.,Project PI:Anderson, A.
  • St of FL Appropriation-CIRC Developmental Funds- 09
    Sponsor: State of Florida
    PI (Contact):Cleveland, J.,PI (MPI):Giuliano, A.
  • St of FL Appropriation-Lung CoE Developmental Funds-11
    Sponsor: State of Florida
    PI (Contact):Cleveland, J.,PI (MPI):Haura, E.
  • St of FL Appropriation-CMRC Developmental Funds-10
    Sponsor: State of Florida
    PI (Contact):Cleveland, J.,PI (MPI):Smalley, K.
  • Investigating the role of melanin-carbonyl-DNA and melanin-carbonyl-protein adducts in melanoma pathogenesis
    Sponsor: Moffitt Cancer Center
    PI (Contact):Premi, S.,PI:Boyle, T.
  • Cell free nucleic acid-based biomarkers in advanced prostate cancer
    Sponsor: Nat Institutes of Health
    PI (MPI):Wang, L.
  • Defining and Targeting Epigenetic Plasticity-Driven Drug Resistance and Immune Escape in Melanoma
    Sponsor: Nat Institutes of Health
    PI:Smalley, K.
  • Investigating the Role of a Novel Dendritic Cell Population as a Central Regulator of a Favorable Immune Environment in Melanoma
    Sponsor: Melanoma Research Foundation
    PI:Smalley, K.
  • State Cancer Center Funds-
    Sponsor: State of Florida
    PI:Cleveland, J.
  • Defining and targeting the epigenetic programs involved in melanoma development
    Sponsor: Nat Institutes of Health
    PI:Smalley, K.
  • Institutional Research Grant - Moffitt Cancer Center
    Sponsor: Amer Cancer Society
    PI:Chellappan, S.
  • The trouble with testosterone: delineating how androgen drives melanoma invasiveness and metastasis via fucosylation-regulated cellular adhesion
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Lau, E.
  • Developing ULK3 inhibitors for Multiple Myeloma
    Sponsor: Moffitt Cancer Center
    PI (Contact):Lynch, C.,PI:Lawrence, N.
  • Proposal to evaluate pan-Ras/NRAS inhibitors in melanoma and melanoma brain metastases
    Sponsor: Revolution Medicines Inc
    PI:Smalley, K.
  • Chang A, Chakiryan NH, Du D, Stewart PA, Zhang Y, Tian Y, Soupir AC, Bowers K, Fang B, Morganti A, Teer JK, Kim Y, Spiess PE, Chahoud J, Noble JD, Putney RM, Berglund AE, Robinson TJ, Koomen JM, Wang L, Manley BJ. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022 Oct.82(4):354-362. Pubmedid: 35718636.
  • He Y, Wei C, Sun Z, Cunningham JM, Wang L, Wei Z, Yang P. Genome-wide methylation profiling reveals differentially methylated genes in blood DNA of small-cell lung cancer patients. Precis Clin Med. 2022 Sep.5(3):pbac017. Pubmedid: 35875603. Pmcid: PMC9306013.
  • Ramos LD, Gomes TMV, Quintiliano SAP, Premi S, Stevani CV, Bechara EJH. Biological Schiff bases may generate reactive triplet carbonyls and singlet oxygen: A model study. Free Radical Bio Med. 2022 Aug.191:97-104. Pubmedid: 36049617.
  • Hesterberg RS, Liu M, Elmarsafawi AG, Koomen JM, Welsh EA, Hesterberg SG, Ranatunga S, Yang C, Li W, Lawrence HR, Rodriguez PC, Berglund AE, Cleveland JL. TCR-independent metabolic reprogramming precedes lymphoma-driven changes in T-cell fate. Cancer Immunol Res. 2022 Aug. Pubmedid: 35969234.
  • Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins MB, Boire A, Bosenberg M, Brastianos P, Cahill DP, Chen Q, Ferguson S, Forsyth P, Glitza Oliva IC, Goldberg SB, Holmen SL, Knisely JPS, Merlino G, Nguyen DX, Pacold ME, Perez-Guijarro E, Smalley KSM, Tawbi HA, Wen PY, Davies MA, Kluger HM, Mehnert JM, Hernando E. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2022 Aug. Pubmedid: 35912544.
  • Kaler CJ, Dollar JJ, Cruz AM, Kuznetsoff JN, Sanchez MI, Decatur CL, Licht JD, Smalley KSM, Correa ZM, Kurtenbach S, Harbour JW. BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas. Cancers (Basel). 2022 Jul.14(15). Pubmedid: 35954340. Pmcid: PMC9367253.
  • Bora-Singhal N, Saha B, Mohankumar D, Padmanabhan J, Coppola D, Chellappan S. A Novel PHD2/VHL-mediated Regulation of YAP1 Contributes to VEGF Expression and Angiogenesis. Cancer Res Commun. 2022 Jul.2(7):624-638. Pubmedid: 35937460. Pmcid: PMC9351435.
  • Carper MB, Goel S, Zhang AM, Damrauer JS, Cohen S, Zimmerman MP, Gentile GM, Parag-Sharma K, Murphy RM, Sato K, Nickel KP, Kimple RJ, Yarbrough WG, Amelio AL. Activation of the CREB Coactivator CRTC2 by Aberrant Mitogen Signaling promotes oncogenic functions in HPV16 positive head and neck cancer. Neoplasia. 2022 Jul.29:100799. Pubmedid: 35504112. Pmcid: PMC9065880.
  • Yao Z, Brennan CK, Scipioni L, Chen H, Ng KK, Tedeschi G, Parag-Sharma K, Amelio AL, Gratton E, Digman MA, Prescher JA. Multiplexed bioluminescence microscopy via phasor analysis. Nat Methods. 2022 Jul.19(7):893-898. Pubmedid: 35739310.
  • Meng H, Yao W, Yin Y, Li Y, Ding Y, Wang L, Zhang M. ZG16 promotes T-cell mediated immunity through direct binding to PD-L1 in colon cancer. Biomark Res. 2022 Jul.10(1):47. Pubmedid: 35831911. Pmcid: PMC9281127.
  • Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Jul.113(3):635-647. Pubmedid: 35289298. Pmcid: PMC9250625.
  • Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 Jun.606(7915):797-803. Pubmedid: 35705814.
  • Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022 Jun.30(6):2315-2326. Pubmedid: 35150889. Pmcid: PMC9171150.
  • Sasamoto N, Stewart PA, Wang T, Yoder SJ, Chellappan S, Hecht JL, Fridley BL, Terry KL, Tworoger SS. Lifetime ovulatory years and ovarian cancer gene expression profiles. J Ovarian Res. 2022 May.15(1):59. Pubmedid: 35562768. Pmcid: PMC9102743.
  • Baratchart E, Lo CH, Lynch CC, Basanta D. Integrated computational and in vivo models reveal Key Insights into macrophage behavior during bone healing. PLoS Comput Biol. 2022 May.18(5):e1009839. Pubmedid: 35559958. Pmcid: PMC9106165.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Adhikari E, Liu Q, Burton C, Mockabee-Macias A, Lester DK, Lau E. L-fucose, a sugary regulator of antitumor immunity and immunotherapies. Mol Carcinogen. 2022 May.61(5):439-453. Pubmedid: 35107186. Pmcid: PMC9097813.
  • Tian Y, Soupir A, Liu Q, Wu L, Huang CC, Park JY, Wang L. Novel role of prostate cancer risk variant rs7247241 on PPP1R14A isoform transition through allelic TF binding and CpG methylation. Hum Mol Genet. 2022 May.31(10):1610-1621. Pubmedid: 34849858. Pmcid: PMC9122641.
  • Lawrence KP, Delinasios GJ, Premi S, Young AR, Cooke MS. Perspectives on Cyclobutane Pyrimidine Dimers-Rise of the Dark Dimers. Photochem Photobiol. 2022 May.98(3):609-616. Pubmedid: 34706095.
  • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 May.8(3):784-793. Pubmedid: 33994165.
  • Tan ES, Knepper TC, Wang X, Permuth JB, Wang L, Fleming JB, Xie H. Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer. Cancers (Basel). 2022 Apr.14(9). Pubmedid: 35565354. Pmcid: PMC9101426.
  • Lin HY, Tseng TS, Wang X, Fang Z, Zea AH, Wang L, Pow-Sang J, Tangen CM, Goodman PJ, Wolk A, Håkansson N, Kogevinas M, Llorca J, Brenner H, Schöttker B, Castelao JE, Gago-Dominguez M, Gamulin M, Lessel D, Claessens F, Joniau S, The Practical Consortium, Park JY. Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status. Cancers (Basel). 2022 Apr.14(8). Pubmedid: 35454886. Pmcid: PMC9024489.
  • Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
  • Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr.81(4):325-330. Pubmedid: 33303244.
  • Ionescu F, Zhang J, Wang L. Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker. Cancers (Basel). 2022 Mar.14(7). Pubmedid: 35406500. Pmcid: PMC8996910.
  • Huang J, Soupir AC, Wang L. Cell-free DNA methylome profiling by MBD-seq with ultra-low input. Epigenetics. 2022 Mar.17(3):239-252. Pubmedid: 33724157. Pmcid: PMC8920199.
  • Larson NB, McDonnell SK, Fogarty Z, Liu Y, French AJ, Tillmans LS, Cheville JC, Wang L, Schaid DJ, Thibodeau SN. A microRNA Transcriptome-wide Association Study of Prostate Cancer Risk. Front Genet. 2022 Mar.13:836841. Pubmedid: 35432445. Pmcid: PMC9006872.
  • Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Ther. 2022 Mar. Pubmedid: 35332245.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Feb. Pubmedid: 35213727.
  • Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, Beyer A, Smalley KSM, Rodriguez PC, Dukett DR, Forsyth PA, Soyano A, Koski GK, Lima Barros Costa R, Han H, Soliman H, Lee MC, Kalinski P, Czerniecki BJ. Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine. Cancer Immunol Res. 2022 Jan.10(1):108-125. Pubmedid: 34785506.
  • Emmons MF, Smalley KSM. Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma. J Invest Dermatol. 2022 Jan.142(1):18-20. Pubmedid: 34565560.
  • Liu D, Zhu J, Zhou D, Nikas EG, Mitanis NT, Sun Y, Wu C, Mancuso N, Cox NJ, Wang L, Freedland SJ, Haiman CA, Gamazon ER, Nikas JB, Wu L. A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. Int J Cancer. 2022 Jan.150(1):80-90. Pubmedid: 34520569. Pmcid: PMC8595764.
  • Phadke M, Ozgun A, Eroglu Z, Smalley KSM. Melanoma brain metastases: Biological basis and novel therapeutic strategies. Exp Dermatol. 2022 Jan.31(1):31-42. Pubmedid: 33455008.
  • Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L. Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond). 2021 Dec.41(12):1387-1397. Pubmedid: 34520132. Pmcid: PMC8696216.
  • Berglund A, Matta J, Encarnación-Medina J, Ortiz-Sanchéz C, Dutil J, Linares R, Marcial J, Abreu-Takemura C, Moreno N, Putney R, Chakrabarti R, Lin HY, Yamoah K, Osterman CD, Wang L, Dhillon J, Kim Y, Kim SJ, Ruiz-Deya G, Park JY. Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men. Biomolecules. 2021 Dec.12(1). Pubmedid: 35053153. Pmcid: PMC8773891.
  • Huang J, Soupir AC, Schlick BD, Teng M, Sahin IH, Permuth JB, Siegel EM, Manley BJ, Pellini B, Wang L. Cancer Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA. Cancers (Basel). 2021 Nov.13(22). Pubmedid: 34830765. Pmcid: PMC8616264.
  • Alfonso JCL, Grass GD, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Torres-Roca JF, Enderling H. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia. 2021 Nov.23(11):1110-1122. Pubmedid: 34619428. Pmcid: PMC8502777.
  • Amente S, Scala G, Majello B, Azmoun S, Tempest HG, Premi S, Cooke MS. Genome-wide mapping of genomic DNA damage: methods and implications. Cell Mol Life Sci. 2021 Nov.78(21-22):6745-6762. Pubmedid: 34463773. Pmcid: PMC8558167.
  • Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?. Cancers (Basel). 2021 Oct.13(20). Pubmedid: 34680353. Pmcid: PMC8533841.